# 32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer

> **NCT00346281** · PHASE2 · UNKNOWN · sponsor: **pSiMedica Limited** · enrollment: 15 (—)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DEVICE:** 32P BioSilicon

## Key facts

- **NCT ID:** NCT00346281
- **Lead sponsor:** pSiMedica Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-06
- **Primary completion:** —
- **Final completion:** 2008-06
- **Target enrollment:** 15 (—)
- **Last updated:** 2006-06-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00346281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00346281, "32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00346281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*